Clinical trials: Thrombotic Microangiopathies
Thrombotic Microangiopathies
Defibrotide TMA Prophylaxis Pilot Trial
Thrombotic microangiopathy (TMA) is a common complication in the stem cell transplant population. Certain populations within the hematopoietic stem cell transplant (HSCT) population are at a higher risk than others.
- Trial name
- NCT03384693
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Autoimmune Thrombocytopenia
The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.
- Trial name
- NCT01667263
- Testing
- All-trans retinoic acid, Danazol
- Where
- 5 sites in China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Primary Immune Thrombocytopenia
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia.
- Trial name
- NCT03102593
- Testing
- ARGX-113
- Where
- 30 sites in Austria, Belgium and 8 more
- Volunteers
- 38 people
- Sponsor
- argenx
Atypical Hemolytic Uremic Syndrome
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
This was a prospective, open-label study with no participant randomization. Treatment for aHUS was observational and at the discretion of the treating physician.
- Trial name
- EVIDENCE (NCT02614898)
- Testing
- Eculizumab
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 67 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Immune Thrombocytopenia (ITP)
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
ITP patients with low platelet count and active bleeding symptoms are at risk of life-threatening bleeding and therefore require a treatment with a rapid effect, reliable, and sustained.
- Trial name
- IVIORDEX (NCT04968899)
- Testing
- Neofordex®, Intravenous immunoglobulins
- Where
- France
- Volunteers
- 272 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenic Purpura
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and…
- Trial name
- ITP (NCT01719692)
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Thrombotic Thrombocytopenic Purpura
.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
Open, multi-center, observational, prospective cohort study, only disease-indicated treatment, in patients with clinically diagnosed acquired and congenital TTP regardless of gender, ethnicity, and comorbidities, over the age of…
- Trial name
- RGTTP (NCT05389007)
- Where
- Germany
- Volunteers
- 156 people
- Sponsor
- Johannes Gutenberg University Mainz
Primary Immune Thrombocytopenia (ITP)
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in increasing the rate of stable response off treatment at 12 months (SROT-12) in…
- Trial name
- VAYHIT1 (NCT05653349)
- Testing
- Ianalumab, Corticosteroids
- Where
- 111 sites in United States, Argentina and 23 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Immune Thrombocytopenia
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
The purpose of this study is to further evaluate the effects that eltrombopag (and romiplostim) have on platelets in subjects with chronic ITP.
- Trial name
- NCT00902018
- Testing
- Eltrombopag, Romiplostim, healthy controls
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Idiopathic Thrombocytopenic Purpura
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of R788 compared with placebo, and to investigate the safety and efficacy of long term dosing of R788 in patients with chronic idiopathic…
- Trial name
- NCT04132050
- Testing
- R788
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Immune Thrombocytopenia
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of…
- Trial name
- NCT05023915
- Testing
- dexamethasone, diammonium glycyrrhizinate enteric-coated capsule
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Shandong University
Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura
Early Predictive Factors of Cardiac and Cerebral Involvement in TMA
The aim of this study is to determine the frequency of cardiac and cerebral involvements in patients with idiopathic thrombotic microangiopathies on diagnosis.
- Trial name
- MATRISK (NCT02134171)
- Testing
- Biological and imaging investigations
- Where
- France
- Volunteers
- 119 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenic Purpura
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
- Trial name
- NCT02077192
- Testing
- Fostamatinib Disodium
- Where
- 55 sites in United States, Australia and 13 more
- Volunteers
- 123 people
- Sponsor
- Rigel Pharmaceuticals
Immune Thrombocytopenic Purpura (ITP)
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with…
- Trial name
- TAPER (NCT03524612)
- Testing
- eltrombopag
- Where
- 32 sites in United States, Austria and 13 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Primary Immune Thrombocytopenia, Aplastic Anemia
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
This is a multi-center, observational study in patients with Immune Thrombocytopenia (ITP) or aplastic anemia(AA) designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug…
- Trial name
- NCT05333861
- Testing
- hetrombopag
- Where
- China
- Volunteers
- 1,150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
TTP - Thrombotic Thrombocytopenic Purpura
Italian iTTP Registry
ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients…
- Trial name
- NCT06376786
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Fondazione Luigi Villa
Immune Thrombocytopenia (ITP)
Longitudinal Observational Study on Immune Thrombocytopenia
Immune Thrombocytopenia (ITP) is a bleeding disorder characterized by immune-mediated destruction and/or impaired production of platelets, leading to clinical manifestations such as petechiae, purpura, mucosal bleeding, and in…
- Trial name
- NCT07068425
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Immune (Idiopathic) Thrombocytopenic Purpura
Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura
The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.
- Trial name
- ITP (NCT00699140)
- Testing
- IGIV3I Grifols
- Where
- 7 sites in Russia, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- Instituto Grifols, S.A.
Thrombocytopenia, Immune Thrombocytopenia
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis.
- Conditions
- Thrombocytopenia, Immune Thrombocytopenia, Myelodysplasia
- Trial name
- APAT (NCT04800458)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 225 people
- Sponsor
- University Hospital, Bordeaux
Immune Thrombocytopenic Purpura
Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP
This is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in…
- Trial name
- NCT07662525
- Testing
- atorvastatin, NAC, and romiplostim
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital